Metabolic alkalinization by acetate and gluconate

"Metabolic alkalinization by acetate and gluconate" describes the **process by which administration of acetate or gluconate salts (e.g., sodium acetate, sodium gluconate) in intravenous fluids results in conversion to bicarbonate**, which raises blood pH and can produce or worsen **metabolic alkalosis**[1][3][7]. Acetate and gluconate are not targets themselves but are metabolic precursors; they are metabolized mainly in the liver to generate bicarbonate. This process is relevant during administration of intravenous fluids (such as in parenteral nutrition or dialysis solutions) and is a recognized cause of metabolic alkalosis[1][3][7]. There is no molecular target such as a receptor or enzyme specifically called "Metabolic alkalinization by acetate and gluconate"; rather, various physiological pathways (e.g., acetate metabolism via the TCA cycle, renal bicarbonate handling) are involved in the overall result. **Supporting context and details:** - Acetate and gluconate **salts** are metabolized into bicarbonate, which can increase extracellular fluid bicarbonate and cause or contribute to alkalinization[1][3][7]. - **Metabolic alkalosis** can occur with excess intake of sodium acetate, sodium gluconate, sodium citrate, and other bicarbonate precursors[1][3]. - The underlying mechanism is metabolic conversion (mainly hepatic) of these anions to bicarbonate[1]. - No **receptor**, **enzyme**, **transporter**, or other distinct molecular target is specifically implied by this term. **Summary of error:** - The provided name is a description of a clinical or metabolic process, not a molecular target; therefore, it should not be classified as a therapeutic target or assigned canonical molecular target properties[1][3][7].